Chief Operating Officer and Treasurer · Sage Therapeutics, Inc. (SAGE)

Christopher Benecchi

A named executive officer of Sage Therapeutics in every fiscal year CompBrief holds from FY2021 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$2,604,988

Salary $532,236Stock awards $1,365,700Bonus $40,000

FY2023: $2,280,917

3rd of 6 named executive officers at Sage Therapeutics by FY2024 total.

6 named officers on file for Sage Therapeutics, FY2024

Christopher Benecchi’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 9 equity grants, each cited to its filing
  • SAGE’s disclosed peer group of 19 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Sage Therapeutics’s whole pay program stands against its peers

  • Sage Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on SAGE→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 24, 2025 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get Christopher Benecchi’s full pay file as a PDF — free

More than this page: up to 10 years of Christopher’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Christopher Benecchi compensation by year

Sage Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as Sage Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2021FY2022FY2023FY2024
Salary$133,334$461,086$501,125$532,236
Bonus$200,000$26,184$0$40,000
Stock awards$1,019,025$643,312$977,524$1,365,700
Option awards$1,324,058$518,633$626,149$481,488
Non-equity incentive$55,699$209,475$165,371$179,200
Pension and deferred compensation$0$0$0$0
All other$314$7,014$10,748$6,364
Total$2,732,430$1,865,704$2,280,917$2,604,988

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Sage Therapeutics, Inc. DEF 14A filed April 24, 2025, accession 0000950170-25-058060, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Sage Therapeutics, Inc. filed document, accession 0000950170-25-058060. Every figure is read from that document and cited to the page and table it appears in. Filed April 24, 2025.

$2.7M
$1.9M
$2.3M
$2.6M
FY21
FY22
FY23
FY24
SalaryBonusNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
PSU17,050$92,582—
PSU16,200$87,966—
PSU15,750$85,523—
PSU13,500$73,305—
PSU9,300$50,499—
PSU8,100$43,983—
PSU7,750$42,083—
PSU7,500$40,725—
PSU6,250$33,938—
Option3,562—$31.36
Option8,437—$45.29
Option12,500—$6.05

Per the Outstanding Equity Awards at Fiscal Year-End table in Sage Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.

Insider transactions since the last proxy

4 Form 4 lines since the FY2024 proxy (filed April 24, 2025)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-07-31Disposition to the issuer—28,053—0
2025-07-31Disposition to the issuer derivative—40,000—0
2025-07-31Disposition to the issuer—36,375—0
2025-07-31Disposition to the issuer derivative—12,500—0

The 4 most recent of 4 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Sage Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
Barry GreeneChief Executive Officer and President$7,112,589
Kimi IguchiFormer Chief Financial Officer and Treasurer$3,067,675
Christopher Benecchi · this pageChief Operating Officer and Treasurer$2,604,988
Anne Marie CookFormer Senior Vice President, General Counsel and Secretary$2,581,710
Laura GaultFormer Chief Medical Officer$2,203,053
Gregory ShifermanSenior Vice President, General Counsel and Secretary$1,169,668

The full Sage Therapeutics compensation record

free company brief

This page is one person within Sage Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Sage Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Sage Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Christopher Benecchi's compensation dossier · One-time report. No refunds.